Claims for Patent: 9,937,129

Summary for Patent: 9,937,129

Title:	Materials and methods for delivering compositions to selected tissues
Abstract:	This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.
Inventor(s):	Freeman; William R. (Del Mar, CA), Sailor; Michael J. (La Jolla, CA), Cheng; Lingyun (San Diego, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	15/004,790
Patent Claims:	1. A method of preparing a composition for controlled drug delivery comprising: providing a porous silicon film; heating the porous silicon film in an oxidizing environment at a temperature above 600.degree. C., preparing particles from the oxidized porous silicon film; and treating the oxidized porous silicon particles with a drug or biologically active material. 2. The method of claim 1, wherein the particles have a size of between about 0.1 .mu.m and about 100 .mu.m. 3. The method of claim 1, wherein the porous silicon film comprises pores with a free volume of from 50% to 80%. 4. The method of claim 1, wherein the drug or biologically active material is a protein. 5. The method of claim 4, wherein the drug or biologically active material is bevacizumab, ranibizumab, or pegaptanib. 6. The method of claim 1, wherein the drug of biologically active material is selected from the group consisting of angiostatic steroids, metalloproteinase inhibitors, VEGF binding drugs, PEDF, an 8-mer peptide fragment of urokinase (uPA), and dexamethasone. 7. The method of claim 1, wherein the drug or biologically active material targets a disease or disorder of the eye. 8. The method of claim 7, wherein the disease or disorder of the eye is selected from the group consisting of: age-related macular degeneration (AMD), choroidal neovascularization (CNV), uveitis, diabetic retinopathy, retinovasclar disease, retinal detachment (PVR), and glaucoma. 9. The method of claim 1, wherein the porous silicon film comprises a layered nanostructure. 10. The method of claim 1, comprising the step of heating the porous silicon film in an oxidizing environment at a temperature above 700.degree. C. 11. The method of claim 1, comprising the step of heating the porous silicon film in an oxidizing environment at a temperature above 800.degree. C. 12. The method of claim 1, wherein particles are prepared from the oxidized porous silicon film after the porous silicon film is heated in an oxidizing environment at a temperature above 600.degree. C. 13. The method of claim 1, wherein the porous silicon film comprises pores selectively dimensioned to obtain a desired reflective wavelength. 14. The method of claim 1, further comprising the step of capping the porous silicon film with a polymeric material. 15. The method of claim 1, wherein the porous silicon film comprises pores configured to enhance binding efficacy of the drug or biologically active material.

Details for Patent 9,937,129

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2025-10-31
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2025-10-31
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2025-10-31
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2025-10-31
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2025-10-31
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2025-10-31